|Bid||225.82 x 1200|
|Ask||226.08 x 900|
|Day's range||223.93 - 230.29|
|52-week range||180.93 - 348.67|
|Beta (5Y monthly)||0.62|
|PE ratio (TTM)||215.10|
|Earnings date||21 Feb 2024 - 26 Feb 2024|
|Forward dividend & yield||N/A (N/A)|
|1y target est||255.50|
The mean of analysts' price targets for Penumbra (PEN) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Penumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT.
Penumbra (PEN) expects to materially increase both revenues and profitability of the international business in the next three years and beyond.